Clinical effect of yindanpinggan capsule and tenofovir on chronic hepatitis B cirrhosis
CHEN Jiyong
Abstract：Objective:To explore the effect of the clinical effect of YindanPinggan Capsule and tenofovir in patients with chronic hepatitis B(CHB)cirrhosis(LC).Methods:A total of 80 CHB LC patients from January 2021 to October 2023 who were admitted in Lianjiang County General Hospital were selected,and randomly divided into the observation group(n=40,YindanPinggan Capsule and tenofovir)and the control group(n=40,tenofovir).The clinical efficacy,liver function indicators,liver fibrosis indicators,and adverse reactions were compared in both groups.Results:The total effective rate of the observation group(95.0％)was higher than that of the control group(77.5％),with statistical significance(P＜0.05).After treatment,the gamma glutamyltransferase(GGT),alanine aminotransferase(ALT),to-tal bilirubin(TBiL),aspartate aminotransferase(AST),alkaline phosphatase(ALP)levels in both groups were de-creased(P＜0.05),and the observation group was lower than control group(P＜0.05).After treatment,laminin(LN),type Ⅲ procollagen peptide amino terminal peptide(PⅢNP),type Ⅳ collagen(CIV),and serum hyaluronic acid(HA)levels in both groups were decreased(P＜0.05),and the observation group was lower thanthe control group(P＜0.05).The inci-dence of adverse reactions in the observation group was 10.0％,while that in the control group was 17.5％.There was no significant difference between the two groups(P＞0.05).Conclusion:The use of yindanpinggan capsule and tenofo-vir in the treatment of CHB LC patients can improve clinical efficacy,liver function indicators and liver fibrosis indica-tors,and has high safety.
Keywords：yindanpinggan capsuletenofovirchronic hepatitis Bcirrhosisclinical effect
Publication Date：2025-04-10
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 272-275 )